0001415889-22-008969.txt : 20220823 0001415889-22-008969.hdr.sgml : 20220823 20220823161106 ACCESSION NUMBER: 0001415889-22-008969 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220822 FILED AS OF DATE: 20220823 DATE AS OF CHANGE: 20220823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dierks Jeffrey CENTRAL INDEX KEY: 0001821102 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 221187641 MAIL ADDRESS: STREET 1: 630 W. GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 form4-08232022_010849.xml X0306 4 2022-08-22 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001821102 Dierks Jeffrey C/O HARMONY BIOSCIENCES HOLDINGS, INC. 630 W GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462 false true false false CHIEF COMMERCIAL OFFICER Common Stock 2022-08-22 4 M 0 28971 24 A 28971 D Common Stock 2022-08-22 4 S 0 26650 46.9543 D 2321 D Common Stock 2022-08-22 4 S 0 2321 47.5637 D 0 D Stock Option 24 2022-08-22 4 M 0 28971 0 D 2030-08-18 Common Stock 28971 86914 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.40 to $47.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.41 to $47.70. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests in five equal annual installments beginning on August 21, 2021. The Form 4 filed by the reporting person on March 2, 2022, overstated the number of securities owned following the reported transaction by 200 shares. The amount of securities reported herein reflects the correct number of securities owned following the transactions reported on this Form 4. /s/ Christian Ulrich, Attorney-in-Fact 2022-08-23